Cardiovascular Diseases

FDA approves Opdivo, Jardiance for new indication, Jemperli gets accelerated approval for solid tumors, and Lilly’s rapid-acting insulin, Lyumjev is approved for administration via an insulin pump.

Positive trial results were reported in The Lancet last year. The FDA is scheduled (the PDUFA date) to make a decision on the application for approval early next year.

Study finds antibiotics, antidepressants, anti-platelets and other drugs contribute to adverse events and mortality.

Keytruda loses one indication but gains another, Biogen narrows use of Aduhelm, Padcev gets regular approval and expanded indication, Amgen submits application for asthma biologic, agency issues complete response letter for diabetes prevention therapy teplizumab, Novartis resubmits NDA for inclisiran.

Data presented at the virtual Sleep 2021 meeting by the Annual American Academy of Sleep Medicine suggests treating sleep apnea or obstructive sleep apnea is important for heart health and better prevents chances of COVID-19.

The study, which will be presented next week during the 70th American College of Cardiology Scientific Session, is the first to examine how chest pain is managed among adults who are too young for Medicare.

Paying attention to the social determinants of health may be a powerful way of improving cardiovascular outcomes.

Access to care and other health disparities result in the low use of novel therapies for Black, female and lower income type 2 diabetes patients. If these barriers aren't addressed, disparities among kidney and cardiovascular patients may worsen in the U.S.

February is American Heart Month and the perfect time to think about our cardiovascular health. Cardiovascular diseases are those that affect the heart and blood vessels and include stroke, coronary artery disease (CAD), heart failure, and other poor heart and vascular health outcomes.

Novartis says the drug may be appropriate for five out of six Americans with chronic heart failure.

The approval come following the results of a phase 3 trial.

The prevalence of heart failure is increasing as the demographic profile of the American population gets older.

Attention is turning this year to heart failure with preserved injection fraction.

Using AI and real-world data, investigators identify drugs that can be used to treat heart disease.

New study findings demonstrate patients with treatment-resistant hypertension rarely get tested for primary aldosteronism.

The panel supports an expanded indication but struggles to reach consensus on what an expanded label might look like.

The NDA submission comes following the results of a phase 3a trial.

Women have an increased risk of heart disease in the years leading up to menopause.

The idea that social factors affect health outcomes is not new, but new research suggests total number of social determinants of health is a valuable proxy for coronary heart disease risk.

Women are disproportionately affected by heart failure after heart attacks, according to a Canadian study.

While glucocorticoids are widely used to reduce inflammation in patients with many inflammatory diseases, doctors don’t know whether a low to moderate glucocorticoid dose increases cardiovascular risk.

FDA approves several drugs to treat rare conditions in both cancer and metabolic diseases.

Entresto (sacubitril-valsartan) didn’t get a lot of love from payers after it was approved in 2015 because of its expense and the crowded armamentarium for heart failure. But Entresto has since made its way into guidelines for reduced ejection fraction heart failure, sometimes called systolic heart failure.

Updates from the American Heart Association Scientific Sessions.

A Cleveland Clinic scientist stopped short of saying doctors should take patients off Vascepa, but he said he has questions due to the lack of a "neutral comparator."

Overall, the Polycap polypill (simvastatin, atenolol, hydrochlorothiazide, ramipril) falls well short of the high expectations for the polypill approach to cardiovascular disease risk reduction.

The findings are the first in a series of six studies involving a registry supported by drug makers in the diabetes, cardiovascular, and heart failure space.

The first in a new class of drugs that targets the cardiac muscle is especially effective in patients with the most serious heart failure.

Biogen's controversial therapy hits headwinds with panel; stroke indication for Brilinta.